<DOC>
	<DOC>NCT00690820</DOC>
	<brief_summary>This study will assess the effect of pancrelipase delayed release 12,000 unit capsules on fat and nitrogen absorption in subjects 7 - 11 with pancreatic exocrine insufficiency due to Cystic Fibrosis.</brief_summary>
	<brief_title>Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Confirmed CF diagnosis by two positive chloride sweat tests or gene analysis Confirmed PEI by historical Coefficient of fat Absorption &lt; 70% without supplementation or current or historical fecal elastase &lt; 50µg/stool (within the last 12 months) Currently receiving treatment with a commercially available pancreatic enzyme product on a stable dose for more than 3 months Clinically stable condition without evidence of acute respiratory disease or any other acute condition Stable body weight and agrees to abstain from sexual activity Ileus or acute abdomen History of fibrosing colonopathy, celiac disease, gastrectomy, Crohn´s disease and small bowel surgery other than minor resection due to meconium ileus without resulting in malabsorption syndrome History of distal ileal obstruction syndrome within 6 months of enrollment Use of an immunosuppressive drug Any type of malignancy involving the digestive tract in the last 5 years Known infection with HIV</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Pancreatic Exocrine Insufficiency</keyword>
</DOC>